<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03842943</url>
  </required_header>
  <id_info>
    <org_study_id>181095</org_study_id>
    <nct_id>NCT03842943</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Combination Immunotherapy for Stage III Melanoma</brief_title>
  <official_title>Neoadjuvant Combination Immunotherapy for Stage III Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene&#xD;
      Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in&#xD;
      resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm Phase 2 study of pre-operative combination immunotherapy with&#xD;
      pembrolizumab and T-VEC given for 6 months prior to complete lymph node dissection for stage&#xD;
      3 resectable cutaneous melanoma with clinically apparent lymph node metastases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response</measure>
    <time_frame>6 months</time_frame>
    <description>Pathologic response rate in the regional nodal basin assessed after complete lymph node dissection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Preoperative T-VEC/pembrolizumab: Adverse events and Serious Adverse Events</measure>
    <time_frame>Every 3-6 weeks during the combination treatment period, and every 3 months after surgery through study completion, up to 5 years</time_frame>
    <description>Adverse events and Serious Adverse Events will be collected</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Cutaneous Melanoma</condition>
  <arm_group>
    <arm_group_label>Combination T-VEC/Pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative talimogene laherparepvec (T-VEC) with Pembrolizumab&#xD;
T-VEC - intra-lesional injection into palpable lymph nodes every 3 weeks for 6 months, or until complete response of target tumors.&#xD;
Pembrolizumab - administered intravenously every 3 weeks for 6 months, then every 3 weeks for one year in the adjuvant setting following complete lymph node dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Preoperative infusions</description>
    <arm_group_label>Combination T-VEC/Pembrolizumab</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Talimogene Laherparepvec</intervention_name>
    <description>Preoperative intralesional injection</description>
    <arm_group_label>Combination T-VEC/Pembrolizumab</arm_group_label>
    <other_name>T-VEC</other_name>
    <other_name>Imlygic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age, any race or sex, who have pathologically confirmed cutaneous melanoma&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Adequate hematologic, hepatic, renal and coagulation function&#xD;
&#xD;
          -  Must have measurable disease and have an injectable target lymph node for&#xD;
             intralesional therapy administration&#xD;
&#xD;
          -  Primary melanoma has been resected&#xD;
&#xD;
          -  Pathologically confirmed resectable stage III disease, clinically apparent.&#xD;
             Resectability is at the discretion of the treating surgeon who is a melanoma&#xD;
             specialist.&#xD;
&#xD;
          -  Stage III disease can be at time of diagnosis of primary melanoma or a recurrence&#xD;
             after initial treatment of stage I-II disease.&#xD;
&#xD;
          -  BRAF mutant or wild type allowed (mutations status not necessary for enrollment)&#xD;
&#xD;
          -  Signed, written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cannot have metastatic (AJCC M1) disease&#xD;
&#xD;
          -  No primary mucosal or uveal melanoma&#xD;
&#xD;
          -  No evidence of melanoma associated with immunodeficiency state or history or other&#xD;
             malignancies (other than non-melanoma skin cancer) within the past 3 years&#xD;
&#xD;
          -  May not have been previously treated with T-VEC, any other oncolytic virus,&#xD;
             pembrolizumab, or any other PD-1, PD-L1, or PD-L2 inhibitor&#xD;
&#xD;
          -  Must not have a history or evidence of symptomatic autoimmune pneumonitis,&#xD;
             glomerulonephritis, vasculitis, or other symptomatic autoimmune disease, document&#xD;
             history of autoimmune disease or syndrome requiring systemic treatment in the past two&#xD;
             years (i.e. use of disease modifying agents, steroids, or immunosuppressive agents)&#xD;
             except vitiligo or resolved childhood asthma/atopy, or evidence of clinically&#xD;
             significant immunosuppression&#xD;
&#xD;
          -  Must not have active herpetic skin lesions or prior complications of herpetic&#xD;
             infection and must not require intermittent or chronic treatment with an anti-herpetic&#xD;
             drug (e.g. acyclovir) other than intermittent topical use&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Egger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Louisville</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Egger, MD</last_name>
    <phone>502-629-6950</phone>
    <email>michael.egger@louisville.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Baum</last_name>
      <phone>502-562-4370</phone>
      <email>mary.baum@louisville.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2019</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Michael Egger</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Talimogene laherparepvec</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

